FDA approves Amgen’s Repatha for heart attack and stroke prevention

Check out Repatha FDA approval news where we will tell you about the approval of the Amgen cholesterol drug for the prevention of heart attack and stroke.

FDA approves Amgen’s Repatha for heart attack and stroke prevention

In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart attacks, strokes, and coronary revascularizations in adults with heart disease. This marks the first approval of a PCSK9 inhibitor for these specific conditions, highlighting a major step forward in the […]

FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients

FDA approves Novo Nordisk’s Victoza for cardiovascular disease treatment in type 2 diabetes patients

Novo Nordisk’s diabetes medication, Victoza (liraglutide), has gained U.S. Food and Drug Administration (FDA) approval for an expanded use, marking a significant step forward in the treatment of cardiovascular diseases among type 2 diabetes patients. This latest approval allows Victoza to be used to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular […]

FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients

Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the US FDA for treating major cardiovascular diseases associated with type 2 diabetes.

FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients

In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use its diabetes drug Victoza (liraglutide) for treating heart diseases associated with type 2 diabetes. This approval marks a pivotal expansion of Victoza’s usage, positioning it as a key player in […]